TissGeneSummary for SEPT14 |
Gene summary |
Basic gene information | Gene symbol | SEPT14 |
Gene name | septin 14 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 7p11.2 | |
Type of gene | protein-coding | |
RefGenes | NM_207366.2, | |
Description | septin-14 | |
Modification date | 20141207 | |
dbXrefs | MIM : 612140 | |
HGNC : HGNC | ||
Ensembl : ENSG00000154997 | ||
HPRD : 16972 | ||
Vega : OTTHUMG00000129341 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_SEPT14 | |
BioGPS: 346288 | ||
Pathway | NCI Pathway Interaction Database: SEPT14 | |
KEGG: SEPT14 | ||
REACTOME: SEPT14 | ||
Pathway Commons: SEPT14 | ||
Context | iHOP: SEPT14 | |
ligand binding site mutation search in PubMed: SEPT14 | ||
UCL Cancer Institute: SEPT14 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of SEPT14 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for SEPT14 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for SEPT14 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for SEPT14 |
TissGeneSNV for SEPT14 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.S156Y | SARC | 2 |
p.G219D | STAD | 1 |
p.G317C | LUSC | 1 |
p.E369* | UCEC | 1 |
p.R359Q | UCEC | 1 |
p.E276K | CESC | 1 |
p.G64E | SKCM | 1 |
p.Q224K | LUAD | 1 |
p.E414K | SKCM | 1 |
p.D15N | CESC | 1 |
p.E371K | LUAD | 1 |
p.Q346* | BLCA | 1 |
p.E294V | BLCA | 1 |
p.D176Y | ACC | 1 |
p.E276K | SKCM | 1 |
p.H278Y | SKCM | 1 |
p.K397N | CESC | 1 |
p.G64R | SKCM | 1 |
p.R157H | COAD | 1 |
p.G317D | SKCM | 1 |
p.E388D | LUSC | 1 |
p.N277Y | SKCM | 1 |
p.L91F | BLCA | 1 |
p.K410* | BLCA | 1 |
p.D376V | LUAD | 1 |
p.L289I | READ | 1 |
p.R264H | KIRC | 1 |
p.V158I | STAD | 1 |
p.C37Y | BRCA | 1 |
p.P323R | GBM | 1 |
p.E369K | BLCA | 1 |
p.P9T | LUAD | 1 |
p.P127Q | ESCA | 1 |
p.G116D | BRCA | 1 |
p.G59_splice | LUSC | 1 |
p.N218H | LUAD | 1 |
p.H304Q | LUAD | 1 |
p.I12M | BRCA | 1 |
p.E364K | SKCM | 1 |
p.Q344* | SKCM | 1 |
p.K425M | LUAD | 1 |
p.A411G | SKCM | 1 |
p.I128M | GBM | 1 |
p.A196V | SKCM | 1 |
p.Q205R | BLCA | 1 |
p.L105F | LUSC | 1 |
p.R25C | SKCM | 1 |
p.M287I | BLCA | 1 |
p.R390M | BLCA | 1 |
p.R25H | STAD | 1 |
p.R48Q | BLCA | 1 |
p.G50E | SKCM | 1 |
p.G317V | LUSC | 1 |
p.R157C | SKCM | 1 |
p.Q224R | LUAD | 1 |
p.Q118E | LUAD | 1 |
p.E362K | SKCM | 1 |
p.V103I | STAD | 1 |
p.P39H | HNSC | 1 |
p.A138T | UCEC | 1 |
p.R157L | LUSC | 1 |
p.D252Y | UCEC | 1 |
p.H429Y | LUAD | 1 |
p.R25C | STAD | 1 |
p.E137Q | BRCA | 1 |
p.L150S | SKCM | 1 |
p.S156Y | UCEC | 1 |
p.H278R | HNSC | 1 |
p.R148C | READ | 1 |
p.G59V | LUAD | 1 |
p.A235P | LUAD | 1 |
p.M383I | SKCM | 1 |
p.E332* | UCEC | 1 |
p.D133N | SKCM | 1 |
p.A138T | LGG | 1 |
p.K283M | LUAD | 1 |
p.S66L | STAD | 1 |
p.D79N | SKCM | 1 |
p.Q417P | OV | 1 |
p.A2V | PRAD | 1 |
p.E253K | ESCA | 1 |
p.R25C | LGG | 1 |
p.R25S | LUAD | 1 |
Top |
TissGeneCNV for SEPT14 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for SEPT14 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | FusionScan | LGG | TCGA-HW-A5KK-01A | SUMF2-SEPT14 | In-Frame | chr7:56146201 | chr7:55886916 |
TCGAfusionPortal | PRADA | GBM | TCGA-06-0211-01A | LANCL2-SEPT14 | In-frame | Chr7:55479782 | Chr7:55886916 |
TCGAfusionPortal | PRADA | GBM | TCGA-06-0750-01A | EGFR-SEPT14 | In-frame | Chr7:55268106 | Chr7:55863785 |
TCGAfusionPortal | PRADA | GBM | TCGA-27-1837-01A | EGFR-SEPT14 | In-frame | Chr7:55268106 | Chr7:55863785 |
TCGAfusionPortal | PRADA | GBM | TCGA-28-1747-01C | EGFR-SEPT14 | In-frame | Chr7:55268106 | Chr7:55863785 |
TCGAfusionPortal | PRADA | GBM | TCGA-28-2513-01A | EGFR-SEPT14 | In-frame | Chr7:55268106 | Chr7:55863785 |
TCGAfusionPortal | PRADA | GBM | TCGA-28-2513-01A | LANCL2-SEPT14 | In-frame | Chr7:55433922 | Chr7:55914330 |
TCGAfusionPortal | PRADA | GBM | TCGA-28-5208-01A | COBL-SEPT14 | In-frame | Chr7:51203855 | Chr7:55886916 |
TCGAfusionPortal | PRADA | GBM | TCGA-32-5222-01A | EGFR-SEPT14 | In-frame | Chr7:55268106 | Chr7:55863785 |
TCGAfusionPortal | PRADA | GBM | TCGA-32-5222-01A | RP11-15K19.2-SEPT14 | 5UTR-CDS | Chr7:55974072 | Chr7:55914330 |
TCGAfusionPortal | PRADA | HNSC | TCGA-CR-7368-01A | EGFR-SEPT14 | In-frame | Chr7:55087058 | Chr7:55874951 |
TCGAfusionPortal | PRADA | LGG | TCGA-DU-6406-01A | EGFR-SEPT14 | In-frame | Chr7:55268106 | Chr7:55863785 |
TCGAfusionPortal | PRADA | LGG | TCGA-DU-A5TY-01A | SEPT14-UPP1 | In-frame | Chr7:55929636 | Chr7:48141421 |
Top |
TissGeneNet for SEPT14 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for SEPT14 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for SEPT14 |
TissGeneDrug for SEPT14 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for SEPT14 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0017636 | Glioblastoma | 1 | BeFree,CTD_human |
umls:C0206726 | gliosarcoma | 0 | ORPHANET |
umls:C0334588 | Giant Cell Glioblastoma | 0 | ORPHANET |